Clinical trials: Grass Pollen Allergy
Allergy
Tolerability of ALK Grass Tablet in Children
The purpose of this trial is to assess whether the ALK Grass tablet treatment is safe to use in children aged 5-12 years
- Trial name
- NCT00310453
- Testing
- ALK Grass tablet
- Where
- Spain
- Volunteers
- 32 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis
Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen
The objective of this study is to assess the efficacy and safety of cluster immunotherapy with highly polymerized allergen extracts.
- Trial name
- NCT01012531
- Testing
- Subcutaneous injections with highly polymerized allergen extract
- Where
- Germany
- Volunteers
- 121 people
- Sponsor
- Roxall Medizin
Grass Pollen Allergy
Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy
The study will evaluate the dose response of immunotherapy against grass pollen allergy using the recombinant grass pollen vaccine BM32.
- Trial name
- NCT01445002
- Testing
- BM32
- Where
- Austria
- Volunteers
- 79 people
- Sponsor
- Biomay AG
Birch Pollen Allergy, Grass Pollen Allergy
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
About 20% of the general population are affected by an allergy - with an upward trend. Quite often, allergic people do not consider their disease as serious and suffer from subsequent complications, like allergic asthma, later in…
- Conditions
- Birch Pollen Allergy, Grass Pollen Allergy, House Dust Mite Allergy, Cat Allergy
- Trial name
- MADMAX (NCT04435678)
- Testing
- ALEX² test using the MAX 45k automated laboratory system
- Where
- 2 sites in Austria
- Volunteers
- 839 people
- Sponsor
- MacroArray Diagnostics GmbH
Seasonal Allergic Rhinitis
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of…
- Trial name
- G104 (NCT03931993)
- Testing
- Grass MATA MPL
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allergy Therapeutics